Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT02979561
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT02979561
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Unknown status
Technical summary
Registry record NCT02979561. Randomized; no masking; primary purpose treatment. Start 2016-10 (registry gives no type); primary completion 2018-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
- Acronym
- Re-Spire
- Condition
- Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy
- Intervention (Drug)
- Dabigatran Etexilate
- Intervention (Drug)
- Warfarin
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
Record details
- Record id
cardio:ct-nct02979561- Content hash
a01fa7cdbc93d5b55a42fb126c733c643bf58876cd8481f9072ed391a893e197